Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson: Dan Waldmann, federal affairs & reimbursement director for devices, will become VP-government affairs of Tenet Healthcare June 8. Waldmann has spent about 11 years in the device industry and two at J&J. He formerly ran his own consultancy; clients included St. Jude Medical and the Medical Device Manufacturers Association. Currently, Waldmann serves as AdvaMed's representative on CMS' competitive bidding Program Advisory & Oversight Group. In his new capacity, Waldmann will direct Tenet's office in Washington, D.C. and oversee state legislative goals. He also will track acute care, inpatient, outpatient and specialty hospital payment policies, GPOs and gainsharing, and will work with hospital groups and the Association of American Medical Colleges. Waldmann's replacement at J&J ostensibly could come from Guidant, following merger of the two firms and their respective D.C. offices...

You may also be interested in...



Viscogliosi Bros. Spawns Small Bone/Joint Orthopedics Firm

Small Bone Innovations, an orthopedics company created by venture capital firm Viscogliosi Brothers, expects to bring the Refix resorbable trauma system to the U.S. market by the end of 2005

Kodak Looks To CAD, Healthcare IT To Grow Digital Medical Division

Kodak will partner with R2 Technology to develop a second-generation lung nodule computer-aided detection (CAD) system and further its expansion into the healthcare sector, the firm says

Possis Jets Into Uncharted Waters With Deep Vein Thrombosis Research

Possis Medical is shifting its R&D efforts away from coronary indications toward finding ways to treat deep vein thrombosis and pulmonary embolism with its AngioJet Rheolytic thrombectomy system

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel